Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence

Area of Science:

• Cardiovascular disease
• Endocrinology
• Women's health

Background:

• The relationship between postmenopausal hormone therapy (HT) and cardiovascular disease (CVD) is complex and debated.
• Epidemiologic studies suggest HT may benefit primary prevention of coronary artery disease (CAD), while secondary prevention trials show mixed results.
• Long-term use of HT in healthy women may reduce CAD risk, with progestin addition not negating benefits.

Purpose of the Study:

• To review and synthesize current evidence on the cardiovascular effects of postmenopausal hormone therapy.
• To evaluate the impact of HT on coronary artery disease, venous thromboembolism, and stroke.
• To inform clinical decision-making regarding HT prescription for postmenopausal women.

Main Methods:

• Review of epidemiologic studies and clinical trials, including primary and secondary prevention trials.
• Analysis of data from large cohort studies like the Nurses' Health Study.
• Assessment of outcomes related to coronary artery disease, venous thromboembolism, and stroke.

Main Results:

• Epidemiologic data consistently suggest a reduced risk of CAD with long-term HT in healthy women.
• Secondary prevention trials have not demonstrated a clear benefit for CAD.
• A significantly increased risk of venous thromboembolism is consistently observed with HT use.
• Data regarding stroke risk are inconclusive, with little evidence of benefit for either ischemic or hemorrhagic stroke.

Conclusions:

• Postmenopausal hormone therapy presents a complex risk-benefit profile for cardiovascular health.
• While HT may offer primary prevention benefits for CAD, the increased risk of venous thromboembolism is a significant concern.
• Individualized assessment weighing potential benefits against risks is essential when considering HT for postmenopausal women.